<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2014</study_start_year><data_sharing_plan>IPD Sharing (as of January 2016): No</data_sharing_plan><condition>Metastatic Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Metastatic Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Observational</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2179782</full_dataset_link><location>France</location><study_start_month>2</study_start_month><keyword>Regorafenib, cohort, metastatic colorectal cancer</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting</name><description>This is a largest cohort study aimed to estimate the overall survival of patients been treated with regorafenib for metastatic colorectal cancer (mCRC) within the frame of a french compassionate program.</description><dates><creation>2014-02-15</creation></dates><accession>2179782</accession><cross_references><ClinicalTrials___gov>NCT02310477</ClinicalTrials___gov></cross_references></HashMap>